



PAAM Digital 2021



7th Pediatric Allergy and Asthma Meeting - 12-13 November



FINAL PROGRAMME



Welcome to the PAAM Digital 2021 meeting!

We are offering you the opportunity to explore our rich state-of-the-art scientific content in a truly innovative way. By participating at the meeting you will be able to interact and discuss the latest findings in the exciting field of pediatric allergy and asthma.

Make the most out of your PAAM Digital 2021 experience by:

- **Accessing the meeting's virtual platform with your MyEAACI login information;**
- Tuning in and watching a variety of virtual sessions without missing out;
- Discussing important topics and asking your questions via an interactive Q&A;
- Consulting our vast number of abstracts, posters and webcasted presentations with novel research any time during the meeting and afterwards;

In order to make the most of this digital format, we have split the meeting programme in 3 parts:

Live Scientific Programme

Top-quality scientific sessions, to be delivered to you live during the event. You will find the details of this programme from pages 16 to 28.

Industry Programme

All the valuable content brought to you by our industry partners.

On-Demand Scientific Content

A selection of presentations from both the live and on-demand programmes will be available for viewing during PAAM Digital 2021 and 6 months thereafter.



Welcome message	4	Programme at a Glance - Saturday, 13 November	22
EAACI Committees	6	Programme Description - Saturday, 13 November	23
General Information	7	List of Posters	26
Description of Session Types	8	Sponsorship and Exhibition	30
EAACI Future Events	11	Founder Sponsors	32
EAACI Activity Challenge	12	Company Sponsored Symposia	33
Networking Activities	13	Exhibitor and Sponsor List	36
Programme at a Glance - Friday, 12 November	16	Exhibitor and Sponsor Editorials	37
Programme Description - Friday, 12 November	17		
List of Posters	20		

General Contact

EAACI Headquarters

Hagenholzstrasse 111
3rd Floor
8050 Zurich Switzerland
Tel: +41 44 205 55 33
Email: events@eaaci.org

Press & Media Contact Information

EAACI Headquarters

communications@eaaci.org
Tel: +41 44 205 55 33
The EAACI Media and Embargo Policy is available [here](#).

Social Media Information

Follow EAACI for regular updates on our events, scientific content and more!

- [Facebook](#)
- [Twitter](#)
- [LinkedIn](#)
- [Youtube](#)

Welcome Message



Helen Brough
PAAM Digital 2021 Chair



Stefania Arasi
PAAM Digital 2021 Co-Chair



Aline Sprikkelman
PAAM Digital 2021 Local
Chair



Nicolette Arends
PAAM Digital 2021 Local
Co-Chair

Welcome to PAAM Digital 2021!

We are pleased to welcome you to the EAACI Pediatric Allergy and Asthma Meeting. This focused meeting is a gathering place for internationally renowned experts who are committed to sharing new research and findings and coming up with solutions to the most pressing challenges in the pediatric field. The burden of allergic diseases and asthma in children has been significantly increasing during the last years, among other reasons due to differences in lifestyles, age of food introduction and industrialization.

A cooperative partnership between clinicians managing children with allergic conditions in the hospital, emergency services, schools, parents, and the child is necessary to ensure allergic children are protected. PAAM Digital 2021 provides the platform for ensuring that research and science trickles down to this effect and allows experts worldwide to gain and share knowledge on the most current developments.

We hope you enjoy PAAM Digital 2021 and find here the necessary tools to work towards ensuring the best futures for our children, while guaranteeing the highest standards of care are implemented and shared within our specialty.

BECOME AN EAACI MEMBER

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.



Renew your membership today!

Benefits applied to all categories

- ✓ Free access to online Allergy, PAI and CTA journals
- ✓ Possibility to join Task Forces
- ✓ Full voting rights & eligibility for election
- ✓ 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- ✓ EAACI Annual Congress
Up to 25% discount
- ✓ EAACI Focused Meetings
25% discount
- ✓ EAACI Schools & Master Classes
Up to 40% discount

**For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€.*

Junior Membership (under 36 years old)

Free

- ✓ EAACI Annual Congress
Up to 55% discount
- ✓ EAACI Focused Meetings
Up to 70% discount
- ✓ EAACI Schools & Master Classes
Up to 50% discount
- ✓ Eligibility for EAACI fellowships & Scholarships
- ✓ Eligibility for EAACI events travel grants

EAACI / NAS Dual Membership

30€

- ✓ EAACI Annual Congress
Up to 25% discount
- ✓ EAACI Focused Meetings
25% discount
- ✓ EAACI Schools & Master Classes
Up to 40% discount

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership



PAAM Organising Committee

Helen Brough, EAACI Pediatrics Section Chair 2019 – 2022 / EAACI ExCom Member 2019 - 2022
 Stefania Arasi, EAACI Pediatrics Section Secretary 2019 - 2022
 Aline Sprikkelman, PAAM Digital 2021 Local Chair
 Nicolette Arends, PAAM Digital 2021 Local Co-Chair
 Edward Knol, EAACI Vice-President Congresses

PAAM Scientific Programme Committee

Montserrat Alvaro Lozano, Spain	Susanne Halcken, Denmark	Marielle Pijnenburg, The Netherlands
Stefania Arasi, Italy	Ludger Klimek, Germany	Carmen Riggioni, Spain
Nicolette Arends, The Netherlands	Edward Knol, The Netherlands	Graham Roberts, United Kingdom
Helen Brough, United Kingdom	Gerard Koppelman, The Netherlands	Silvia Sanchez, Spain
Dominique Bullens, Belgium	Rosan Meyer, United Kingdom	Alexandra Santos, United Kingdom
Philippe Eigenmann, Switzerland	Charlotte Mortz, Denmark	Anna Sediva, Czech Republic
Thomas Eiwegger, Canada	Antonella Muraro, Italy	Aline Sprikkelman, The Netherlands
Joyce Emons, The Netherlands	Chris Nieuwhof, The Netherlands	Sophia Tsabouri, Greece
Marta Vasquez, United Kingdom	Christian Vogelberg, Germany	Gary Wong, China

Pediatrics Section Board

Helen Brough, United Kingdom, Chair
 Stefania Arasi, Italy, Secretary
 Elena Galli, Italy, Board member
 Daniel Munblit, Russia, Board member
 Pablo Rodriguez del Rio, Spain, Board member
 Sophia Tsabouri, Greece, Board member
 Marta Vazquez-Ortiz, United Kingdom, Board member
 Burcin Beken, Turkey, JM Representative

EAACI President

Marek Jutel, Poland

EAACI Vice-President Congresses

Edward Knol, The Netherlands



Login Information:

- In order for you to easily access our meeting's online platform we have developed a tool that allows you to use your MyEAACI username and password as your PAAM Online Platform login.
- If you do not remember your MyEAACI username and/or password, please access the platform [here](#) and go through the "Forgot your password?" process.
- Our support team is available to assist you in real time should any questions arise.

Abstracts

All abstracts will be listed on the EAACI website. Presented abstract texts will be published on the EAACI content platform after the event.

Certificate of Attendance

The Certificate of Attendance can be downloaded after completing the delegates survey, which will be sent via email after the event.

CME Credits

The EAACI Pediatric Allergy and Asthma Meeting (PAAM), Digital, Switzerland, 12/11/2021-13/11/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s). Please find more information [here](#).

Disclaimer

Participants are encouraged to purchase an insurance to cover loss incurred in the event of cancellation. EAACI cannot be held liable for any hindrance or disruption of the PAAM Digital 2021 proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control (force majeure). Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

EAACI Campus

Visit the EAACI Campus virtual booth to learn more about EAACI's activities such as membership, publications, EAACI Media Library and future events. The booth will be open throughout the entire congress, and an online team will be available for questions through the live chat during the following hours:

- Friday, 12 November 2021: 08:00 – 18:45 CET
- Saturday, 13 November 2021: 08:00 – 19:15 CET

Photography, film and audio for event documentation and public reporting

By participating in PAAM Digital 2021 the delegate understands that recordings of the digital content and the capture of images and videos to be publicly shared are prohibited.

Registration

Registration fee for delegates includes full access to the event content.

Technical Information

The PAAM Digital 2021 interface will be user-friendly and fully responsive, allowing delegates to watch all sessions from their laptops/desktops, iPad/tablets, and mobile phones. However it is recommended to use computers, to get the best experience including live chat during sessions within the Live Scientific Programme, an important feature that boosts interaction between you, faculty and your peers. In regards to a preferable web browser, we suggest Google Chrome. In order to provide a well streamlined support, we kindly ask you to send any technical queries directly to the following email address: support@eaaci.org.

Timezone

The official PAAM Digital 2021 timezone is CET (Central European Time).

Virtual Exhibition

Join us in meeting with key industry experts, exchange knowledge on critical areas of development and research in allergy and immunology. The digital exhibition will be open according to the main scientific programme timetable, subject to final adjustments:

- Start of Exhibition: 12 November 2021 – 09:00 CET
- End of Exhibition: 12 May 2021 – 17:30 CET

Description of Session Types



Industry Symposia

Industry Symposia will run in parallel to the main scientific programme on the digital platform. These symposia are organised independently by the sponsoring companies who also select the topics and speakers. The topics have been reviewed and approved by EAACI.

Plenary Symposia

Plenary Symposia are the core of EAACI meetings. These are exhaustive reviews of a major subject of the speciality, addressed to all participants. Plenary Symposia are scheduled at “prime times” in the programme. Leading international speakers have been invited to conduct these symposia.

Symposia

Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area.

Poster Sessions

Posters can be found in the e-poster section of the PAAM Digital 2021, together with a voice-over. Poster chairs will interact with the poster presenters during the respective sessions. A prize will be awarded to the best poster presentation in each Poster Session Group.

Pro&Con Sessions

The Pro & Con Sessions allow speakers to debate controversial topics in an attractive format which provides “food for thought”. The session may take the form of a debate where speakers alternate to present their arguments. Each presenter defends his/her position in a short presentation of maximum 15 minutes each, followed by 10 min rebuttal each and discussion with the audience for 10 minutes at the end of the session. The introduction and the conclusion of the Pro & Con session will be fully live, and the audience will be asked to vote at the beginning and the end of the session.

Oral Communication Session

The most exciting work from abstracts submitted to the congress will be honoured with a place in these sessions. Each presenter highlights their work and answers questions from attendees.

Learning Lounge

Special sessions which allow delegates to meet in small groups with outstanding researchers and clinicians in our field. This format is designed to facilitate informal discussions, allowing participants to present their questions and gain new insights.

Workshop

Workshops are sessions in which speakers share and discuss evidence and experience gathered in a certain field. Live interaction with the audience is encouraged.



*Impactful learning to further develop
your knowledge in allergy, asthma and immunology*





Save the date!



EAACI Hybrid Congress 2022

Prague, Czech Republic 1-3 July

Common origins of allergy and chronic inflammatory diseases - One Health approach



Pick your next EAACI Event!



EAACI Hybrid Congress 2022

Common origins of allergy and chronic inflammatory diseases - One Health approach

1-3 July 2022
Physical Congress in Prague & Digital Congress

We are eager to share with you the latest developments in basic, translational and clinical research in allergy, asthma and immunology, and as usual invite your personal valuable contributions, knowledge and enthusiasm, which will ensure the congress' unwavering success. Save the date for our annual congress!

Allergy Schools and Master Classes



Winter School Hybrid 2022
27-30 January 2022

The 20th Immunology Winter School on Basic and Clinical Immunology will take place from 27 to 30 January 2022, in Semmering, Austria in a hybrid format. With an innovative but still highly interactive concept, the meeting will allow you to take part in exciting scientific discussions both on-site and from the safety of your home. Learn more here.

Winter School Hybrid 2022



Master Class on Perioperative Hypersensitivity
19 - 21 April 2022

EAACI Master Classes aim to dive deeper and therefore target professionals and specialists with a higher level of experience. Save the date for this exciting meeting taking place in Verona, Italy on April 2022.

Master Class Verona 2022
Save the date

For more information and registration to our events visit EAACI.org



EAACI Activity Challenge



Overview

Delegates will be able to earn points at several check points and interactions along the way during the PAAM Digital 2021 experience. Your ultimate goal: **win vouchers that can be used towards any EAACI event registration in the future.**

Available to all registered delegates visiting the virtual exhibition area, chatting, answering scientific questions, and providing valuable feedback to our industry partners.

Additionally, with the Leaderboard function, delegates will be able to see the live scores of the top 20 delegates.

EAACI would like to thank our industry sponsors for their support and dedication during these difficult times, This could not be done without their valuable contributions.

The digital information exchange at PAAM Digital 2021 represents a new and exciting experience for us all. We encourage you to explore it! Use your well-deserved breaks to network, get informed and exchange.

How does it work?

- Once you have logged on to the PAAM Digital 2021 platform, the Activity Challenge will appear on the Home Page. Click on the Activity Challenge icon which will prompt a description of the activities.
- The goal is to generate as many points as possible from the group of activities listed.
- Each activity will have a maximum amount of points that can be achieved, which will be distributed based on how much you have completed.
- As activities progress, there are barriers that show:
 - Activity completion status. Eg. You have completed 5/10 activities
 - Your score can be seen next to your profile.
- In the case of a tie between multiple participants in the EAACI Activity Challenge, the winner will be automatically identified based on the submission time of first completing the full Activity Challenge.



Activity Challenge PAAM Digital 2021


Networking Opportunities



Get in touch with your peers and expand your professional network!


Our events' networking tool has been developed to give you the element of interpersonal connection that we are missing from physical events. With just a few clicks you can explore the vast pool of delegates participating in the event, select your connections or view who is recommended to you based on your mutual interests, and start the discussion in a private one-on-one chat. One of EAACI's main goals is fostering such interaction among expert researchers and physicians, as only together the priorities of our specialty can be achieved. We encourage you to make use of the networking tool throughout the meeting.

Attendees List



Delegates can connect, chat and discover like-minded peers attending PAAM Digital 2021. It is possible to search for delegates through different criteria, such as profession, type of working place, location, and country. We recommend you check your pending requests as connection notifications come in. Make sure to update your profile, make it public and join the conversation!

Networking Lobby



This is where delegates meet "face-to-face". Turn on your webcam, activate your microphone and join the networking lobby for real-time interaction with other delegates. Grab your coffee and get ready to make new connections that will expand your professional network, discuss science and the news, or simply catch up with that colleague you haven't been able to see in a long time.



Thousands of resources now available on EAACI Media Library

Guidelines
Abstracts
Books
Posters
Papers



EAACI
WHITE
PAPER


on Research,
novation and
Quality Care



GLOBAL
ATLAS
OF
SKIN ALLERGY

Published by the European Academy of Allergy and Clinical Immunology

www.eaaci.org




Newsletters



Webcasts

All EAACI Resources are only 1 click away



Programme at a Glance



Friday, 12 November 2021

This page gives an overview of the digital sessions organised on Friday 12, 2021.

[Click here to access the On-Demand content](#)

CET Time	Channel 1
08:15 09:45	Plenary Symposium - 8:15 - 9:45 CET The skin barrier: key player in the etiology of atopic dermatitis and allergy
09:45 10:00	Break
10:00 11:15	Symposium - 10:00 - 11:15 CET Severe food allergy: what is it?
11:15 11:30	Break
11:30 13:00	Plenary Symposium - 11:30 - 13:00 CET Environment and immunomodulation: where are we?
13:00 14:15	Break and Learning Lounge Sessions - Find more information here.
14:15 15:45	Plenary Symposium - 14:15 - 15:45 CET Asthma during childhood: from preschool children into adulthood
15:45 16:00	Break
16:00 17:15	Symposium - 16:00 - 17:15 CET Optimizing the diagnosis of IgE mediated food allergy
17:15 17:30	Break
17:30 18:45	Symposium - 17:30 - 18:45 CET Novel approach for food allergy prevention: avoid avoidance

Channel 2
Pro/Con Session - 8:45 - 9:45 CET Combined LABA ICS should be used as step 1 treatment in children with asthma
Oral Communication Session - 10:00 - 11:15 CET Pediatric allergy, epidemiology and COVID-19
11:30 - 12:45 CET Company Sponsored Symposia
13:00 - 14:15 CET Company Sponsored Symposia
14:30 - 15:45 CET Company Sponsored Symposia
16:00 - 17:15 CET Company Sponsored Symposia
Oral Communication Session - 17:30 - 18:45 CET Urticaria and dermatitis

Poster Sessions (Q&A via chat-box in the e-POSTERS section)

13:00 14:15	PS1 Poster session 1 - Group 1 Food allergy: from diagnosis to resolution PS1 Poster session 1 - Group 2 Different aspects of immunotherapy PS1 Poster session 1 - Group 3 Pediatric airway diseases and ocular allergy PS1 Poster session 1 - Group 4 Urticaria, angioedema and drug allergy
----------------	--

Programme description



Friday, 12 November 2021

PLO1 - The skin barrier: key player in the etiology of atopic dermatitis and allergy
8:15 AM - 9:45 CET

Moderators: Alan Irvine, Ireland / Aline Sprickelman, The Netherlands

08:15 - 08:45 - **The exposome in atopic dermatitis**
Alan Irvine, Ireland

08:45 - 09:15 - **Skin barrier and allergic disease in childhood**
Jacob Pontoppidan Thyssen, Denmark

09:15 - 09:45 - **Non-invasive biomarkers of the skin barrier in childhood**
Sanja Kezic, The Netherlands

Pro&Con Session - Combined LABA ICS should be used as step 1 treatment in children with asthma
08:45-09:45 CET

Moderators: Christian Vogelberg, Germany / Monika Gappa, Germany

08:45 - 09:45 - **The arguments Pro**
Louise Fleming, United Kingdom

08:45 - 09:45 - **The arguments Con**
Michiel Banner, The Netherlands

SYM1 Severe food allergy: what is it?
10:00-11:15 CET

Moderators: Alessandro Fiocchi, Vatican City / Giovanni Battista Pajno, Italy

10:00 - 10:25 - **Severe food allergy: what does it look like?**
Stefania Arasi, Italy

10:25 - 10:50 - **Can we identify patients at risk of life-threatening allergic reaction to food?**
Ruchi Gupta, United States

10:50 - 11:15 - **How can we improve the quality of life of patients with severe food allergy?**
Audrey Dunn Galvin, Ireland

OAS 01 Pediatric allergy, epidemiology and COVID-19
10:00-11:15 CET

Moderators: Erik Melén, Sweden / Daniel Munblit, Russia

10:00 - 10:08 - **The clinical burden of cow's milk allergy in childhood – a retrospective cohort study**
Katy Sorensen, United Kingdom

10:08 - 10:13 - **Q&A**

10:13 - 10:21 - **Cow's milk protein-induced allergic proctocolitis: cohort review**
María Fernanda González Germán, Spain

10:21 - 10:26 - **Q&A**

10:26 - 10:34 - **Increased eczema and food allergen sensitisation at 12months in children born during COVID-19 lockdown: the CORAL study**
Sadhbh Hurley, Ireland

10:34 - 10:39 - **Q&A**

10:39 - 10:47 - **Environment and health measures at 12months in children born during COVID-19 lockdown: the CORAL study**
Sadhbh Hurley, Ireland

10:47 - 10:52 - **Q&A**

10:52 - 11:00 - **The effect of the covid-19 pandemic lockdown on symptom severity in school children with house dust mite sensitized allergic rhinitis**
Demet Can, Turkey

11:00 - 11:05 - **Q&A**

Programme description



Friday, 12 November 2021

PL2 Environment and immunomodulation: where are we?

11:30-13:00 CET

Chairs: R.J. Joost van Neerven, The Netherland / Valérie Verhasselt, Australia

11:30 - 12:00 - **Early life microbial exposures and allergy risks: windows for prevention**

Harald Renz, Germany

12:00 - 12:30 - **The impact of milk and its components on epigenetic programming and the development of allergy**

R.J. Joost van Neerven, The Netherlands

12:30 - 13:00 - **Influence of fatty acids in asthma, food allergy and atopic dermatitis**

Caroline Roduit, Switzerland

PL3 Asthma during childhood: from preschool children into adulthood

14:15-15:45 CET

Chairs: Angela Zacharasiewicz, Austria / Carla Jones United Kingdom

14:15 - 14:45 - **The airway microbiota in the development of asthma: time to act?**

Jonathan Thorsen, Denmark

14:45 - 15:15 - **Asthma and obesity in children: unravelling the associations**

Erick Forno, United States

15:15 - 15:45 - **Using endotypes to focus your management of asthma**

Marielle Pijnenburg, The Netherlands

SYM2 Optimizing the diagnosis of IgE mediated food allergy

16:00-17:15 CET

Moderators: Karin Hoffmann-Sommergruber, Austria / Lars K. Poulsen, Denmark

16:00 - 16:25 - **Does allergen component testing make a difference in the practical management of food allergy?**

Ronald van Ree, The Netherlands

16:25 - 16:50 - **Are BAT and MAT ready to become part of clinical practice?**

Alexandra F. Santos, United Kingdom

16:50 - 17:15 - **Oral food challenge versus biomarkers - are challenges still needed?**

Kirsten Beyer, Germany

SYM3 Novel approach for food allergy prevention: avoid avoidance

17:30-18:45 CET

Moderators: Philippe Eigenmann, Switzerland / Mary Jane Marchisotto, United States

17:30 - 17:55 - **When is “early” introduction of food: new EAACI Prevention guidelines and beyond**

Susanne Halken, Denmark

17:55 - 18:20 - **Early introduction of food allergens to prevent IgE mediated allergies – is it feasible in daily practice?**

Helen A Brough, United Kingdom

18:20 - 18:45 - **Diversifying diet: a novel way for prevention?**

Carina Venter, United States

Programme description



Friday, 12 November 2021

OAS 02 Pediatric allergy, epidemiology and COVID-19

17:30-18:45 CET

Moderators: Sophia Tsaouri, Greece / Suzana Radulovic, United Kingdom

17:30 - 17:38 - **Disease burden and treatment of moderate-to-severe atopic dermatitis (AD) in children aged <12 years: results from 732 patients in the PEDISTAD observational study**

Danielle Marcoux, Canada

17:38 - 17:43 - **Q&A**

17:43 - 17:51 - **Developing and validating a clinical prediction model to detect severe, early onset, chronic paediatric multisystem allergy**

Francis Gainsborough, United Kingdom

17:51 - 17:56 - **Q&A**

17:56 - 18:04 - **Clinical characterization and remission predictors of chronic urticaria in pediatric patients**

Mónica Sandoval Ruballo, Spain

18:04 - 18:09 - **Q&A**

18:09 - 18:17 - **Trichinella spiralis infection associated with chronic spontaneous urticaria - case series**

Diyana Ognyanova Ogneva, Romania

18:17 - 18:22 - **Q&A**

18:22 - 18:30 - **Ligelizumab in adolescent patients with chronic spontaneous urticaria: results from a dedicated phase 2b study**

Montserrat Alvaro-Lozano, Spain

18:30 - 18:35 - **Q&A**



Friday, 12 November 2021 - 13:00 - 14:15 CET

Group 1: Food allergy: from diagnosis to resolution

Moderators: Alexandra F. Santos, United Kingdom / Tom Marrs, United Kingdom

Sensitisation to ana o 2 is rare among children with cashew nut allergy
Petteri Röntynen, Finland

Food allergen hazard in on-demand food delivery: a survey in northern Italy
Daniela Manila Bianchi, Italy

Cow's milk allergy evaluation – fresh milk or commercial extracts?
Idit Lachover Roth, Israel

Symptoms and severity of reactions in positive oral food challenges with cow's milk
Otso Lauri Tapio Nieminen, Finland

Low health-related quality of life predicts declining introduction at home of suspected food allergens
Wouter de Weger, The Netherlands

Pediatric alpha-gal syndrome: a not so rare entity
Francesca Saretta, Italy

Allergic contact stomatitis caused by egg
Gonçalo Martins dos Santos, Portugal

Aiming at the optimal recording of medical history of children with suspected LTP-syndrome: clinical audit results
Margarita Tsoplaktsoglou, Greece

Natural history and predictors for persistence of immediate-type egg allergy in chinese children
Ting Fan Leung, Hong Kong SAR

Five steps OFC for the evaluation of tolerance in a patient with FPIES and sigE to fish
Cezara Motei, Romania

Molecular allergy diagnostics in pediatric atopic patients: comparing multiplex sIgE by ISAC and ALEX
Laura Sonneveld, The Netherlands

Group 2: Different aspects of immunotherapy

Moderators: Antoine Deschildre, France / George du Toit, United Kingdom

Immunological outcomes of daily oral immunotherapy for peanut allergy in children and adolescents: longitudinal analyses up to 6 years
Caroline Nilsson, Sweden

Oral immunotherapy in young children with peanut allergy: sustained unresponsiveness after 1 year of treatment
Ted Klok, The Netherlands

Oral immunotherapy in young children with food allergy, a parental perspective
Ted Klok, The Netherlands

Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization in a mouse model of peanut allergy
Jessica J. O'Konek, United States

Continuation of allergy sublingual immunotherapy (lyophilized tablets) in pediatric allergic rhinitis patients using reimbursement claims data in Japan
Yuriko Maekawa, Japan

The role of sublingual allergen immunotherapy with alternaria alternate in the prevention of asthma in children
Olena Victorovna Sharikadze, Ukraine

Low-dose OIT as a safe and feasible treatment to induce sustained unresponsiveness in young children with an allergy to cashew nut
Ted Klok, The Netherlands

Exploring health-related quality of life burden in peanut allergy and the potential benefit of oral immunotherapy
Jane De Vries, United Kingdom



Friday, 12 November 2021 - 13:00 - 14:15 CET

Group 3: Pediatric airway diseases and ocular allergy

Moderators: Dominique Magdalena Andrea Bullens, Belgium / Louise Fleming, United Kingdom

The combination of nasal steroid and anti leukotriene reduces adenectomy in children with OSA and adenoid hypertrophy; the response correlates with allergic sensitization
Manal Yousif Eldegeir, Saudi Arabia

Antimicrobial peptides as a marker of mucosal innate immunity of the upper airways in children with atopic respiratory diseases
Olha Shvaratska, Ukraine

Is eosinophilia during hospitalisation for bronchiolitis associated with asthma or atopy in young adult age?
Karen Galta Sørensen, Norway

Dupilumab improves allergic rhinitis-related health related quality of life in children with uncontrolled persistent asthma with comorbid allergic rhinitis
Alessandro Fiocchi, Vatican City

Atopic prevalence in swedish infants born in 2018 compared with 2003
Frida Strömberg Celind, Sweden

Lung function from birth to age six in moderate to late pre-term children
Fanny Edit Maria Goth, Denmark

The state of the autonomic nervous system in children with allergic rhinitis, depending on the place of residence
Pavel Berezanskiy, Russia

Prevalence of allergic diseases and risk factors in the period of COVID 19 pandemic
Nino Adamia, Georgia

Group 4: Urticaria, angioedema and drug allergy

Moderators: Burcin Beken, Turkey / Marina Atanaskovic-Markovic, Serbia

Chlorhexidine, a hidden allergen with two faces in children
Natalia Rodríguez Otero, Spain

Clinical course of children with nonsteroidal anti-inflammatory drugs allergy
Serap Ozmen, Turkey

Leuprolide acetate associated hypersensitivity reaction in a child diagnosed with central precocious puberty
Seher Tekeli, Turkey

The role of medical history and allergic tests in the analysis of antibiotic allergy in pediatric population
Margarita Dimitroglou, Greece

Dermographism in a pediatric allergy consultation
Aida Correia Azevedo, Portugal

Toxic epidermal necrolysis: the same diagnosis, but different prognoses
Liliana Patrícia Pereira Dias, Portugal

The importance of drug provocation tests in pediatric beta-lactam allergy: a five-year review
Daniela Brandão Abreu, Portugal

Evaluation of antibiotic allergy in children in northern Greece
Nikolaos Kitsos, Sweden

Genetic diagnosis of pediatric hypocomplementemic urticarial vasculitis syndrome
Elena Borzova, United Kingdom

Measles, mumps and rubella vaccination related anaphylaxis in an infant with multiple food allergy
Seher Tekeli, Turkey

Programme at a Glance



Saturday, 13 November 2021

This page gives an overview of the digital sessions organised on Saturday 13, 2021.

[Click here to access the On-Demand content](#)

CET Time	Channel 1	Channel 2
08:15 - 09:45	Plenary Symposium - 8:15 - 9:45 CET Delivering better care to children at risk of anaphylaxis	Oral Communication Session - 8:30 - 9:45 CET Food allergy
09:45 - 10:00	Break	
10:00 - 11:15	Workshop - 10:00 - 11:15 CET How to set up a transition clinic for adolescents and young adults with allergy and asthma?	10:00 AM - 11:15 CET Company Sponsored Symposium
11:15 - 11:30	Break	
11:30 - 13:00	Plenary Symposium - 11:30 - 13:00 CET Epigenetics of allergy	11:30 AM - 12:45 CET Company Sponsored Symposium
13:00 - 14:15	Break and Learning Lounge Sessions - Find more information here.	Oral Communication Session 13:00 - 14:15 CET Latest in immunomodulation in food allergy
14:15 - 15:45	Plenary Symposium - 14:15 - 15:45 CET Immunomodulation in food allergy	Oral Communication Session 14:30 - 15:45 CET Asthma mechanisms and management
15:45 - 16:00	Break	
16:00 - 17:15	Symposium - 16:00 - 17:15 CET Immunomodulation in respiratory allergy	16:00 - 17:15 CET Company Sponsored Symposia
17:15 - 17:30	Break	
17:30 - 18:45	Symposium - 17:30 - 18:45 CET Pediatric mastocytosis: diagnosis, prognosis and management	Pro/Con Session - 17:30 - 18:30 CET Adrenaline auto-injectors: are they fit for purpose?
18:45	Closing ceremony and awards presentation	

Poster Sessions (Q&A via chat-box in the e-POSTERS section)

13:00 - 14:15	PS2 Poster session 2 - Group 1 Novel approaches in asthma PS2 Poster session 2 - Group 2 The spectrum of food allergy management and implications PS2 Poster session 2 - Group 3 Atopic and contact dermatitis PS2 Poster session 2 - Group 4 Immunodeficiency, COVID-19 and other infections PS2 Poster session 2 - Group 5 Prevention and anaphylaxis
---------------	---

Programme Description



Saturday, 13 November 2021

PL4 Delivering better care to children at risk of anaphylaxis

08:15-09:45 CET

Moderators: Stefania Arasi, Italy / Maria Said Australia

08:15 - 08:45 - **Is anaphylaxis really rare in children?**
Antoine Deschildre, France

08:45 - 09:15 - **How can we prevent future fatal anaphylactic episodes**
Graham Roberts, United Kingdom

09:15 - 09:45 - **New visions for managing anaphylaxis. Lesson from EAACI guidelines**
Antonella Muraro, Italy

OAS 03 Food Allergy

08:30-09:45 CET

Moderators: Rosan Meyer, United Kingdom / Kirsten Beyer, Germany

08:30 - 08:38 - **The impact of a digital enabled paediatric dietetic medicines optimisation service for infants with non IgE mediated cow's milk protein allergy**
Lydia Collins-Hussey, United Kingdom

08:38 - 08:43 - **Q&A**

08:43 - 08:51 - **Patterns in diagnostics and prevalence of tree-nut allergy: a retrospective study**
Ted Klok, The Netherlands

08:51 - 08:56 - **Q&A**

08:56 - 09:04 - **From young person to adult - evaluating healthcare transition in real life for 16 year olds seen in a tertiary allergy centre in london**
Anjali Rampersad, United Kingdom

09:04 - 09:09 - **Q&A**

09:09 - 09:17 - **The impact of food allergy myth-busting information on maternal food allergy related quality of life**
Mairead Sheehan, Ireland

09:17 - 09:22 - **Q&A**

09:22 - 09:30 - **Assessment of the methodological quality of srs on early compared to later introduction of allergenic complementary foods and fluids for early childhood allergy prevention**
Uwe Mattered, Germany

09:30 - 09:35 - **Q&A**

WS1 How to set up a transition clinic for adolescents and young adults with allergy and asthma?

10:00-11:15 CET

Moderators: Rebecca Knibb, United Kingdom / Charlotte G. Mortz, Denmark

10:00 - 10:25 - **Why is a transition clinic needed for AYA with allergy and asthma?**
Marta Vazquez-Ortiz, United Kingdom

10:25 - 10:50 - **Evidence-based recommendations for transitional care**
Helena Pite, Portugal

10:50 - 11:15 - **The 'allergy tool kit' for the transition clinic**
Pasquale Comberiati, Italy

PL5 Epigenetics of allergy

11:30-13:00 CET

Moderators: Gerard Koppelman, The Netherlands / Klaus Bønnelykke, Denmark

11:30 - 12:00 - **Epigenetics of allergy: an introduction**
Michael Kabesch, Germany

12:00 - 12:30 - **Environmental epigenomics of allergy**
Erik Melén, Sweden

12:30 - 13:00 - **Epigenetics based diagnosis of allergy**
Juan Carlos Celedón, United States



Saturday, 13 November 2021

OAS 04 Latest in immunomodulation in food allergy

13:00-14:15 CET

Moderators: Pablo Rodríguez del Río, Spain / Montserrat Alvaro Lozano, Spain

13:08 - 13:13 - **Q&A**

13:13 - 13:21 - **Effects of IgE immunoapheresis for the treatment of food – induced severe anaphylaxis: a case series of five children**

Stefania Arasi, Italy

13:21 - 13:26 - **Q&A**

13:26 - 13:34 - **Efficacy of omalizumab in patients with severe food allergy and concomitant asthma**

Stefania Arasi, Italy

13:34 - 13:39 - **Q&A**

13:39 - 13:47 - **Study design of a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab in children aged 1–11 years, with active eosinophilic esophagitis**

Mirna Chehade, United States

13:47 - 13:52 - **Q&A**

13:52 - 14:00 - **Baseline demographics and disease characteristics of patients with eosinophilic esophagitis in part A of the 3-part, randomized, placebo-controlled, phase 3 TREET study**

Marc Rothenberg, United States

14:00 - 14:05 - **Q&A**

PL6 Immunomodulation in food allergy

14:15-15:45 CET

Moderators: Montserrat Alvaro Lozano, Spain / Marcia Po-detà, Italy

14:15 - 14:45 - **Combining immunotherapy for food allergy and biologics: added immunomodulatory effect?**

Aikaterini Anagnostou, United States

14:45 - 15:15 - **Can biomarkers successfully predict food allergy immunotherapy?**

Carmen Riggioni, Singapore

15:15 - 15:45 - **Novelties in mechanisms for food immunotherapy**

Thomas Eiwegger, Canada

OAS 05 Asthma mechanisms and management

14:30-15:45 CET

Moderators: Gerard Koppelman, the Netherlands / Edward Knol, the Netherlands

14:30 - 14:38 - **The role of EGR-1 as a potential biomarker in asthma and proinflammatory responses in airway epithelium**

Yoni Van Dijk, The Netherlands

14:38 - 14:43 - **Q&A**

14:43 - 14:51 - **Dupilumab improves asthma control and health-related quality of life in children with uncontrolled persistent asthma: VOYAGE study**

Alessandro Fiocchi, Vatican City

14:51 - 14:56 - **Q&A**

14:56 - 15:04 - **Weak correlation between percentage of predicted values of PEF and FEV1 parameters in children population**

Mateusz Solinski, Poland

15:04 - 15:09 - **Q&A**

15:09 - 15:17 - **Efficacy of dupilumab in children with uncontrolled, moderate-to-severe type 2 asthma, with/without evidence of allergic asthma: the VOYAGE phase 3 study**

Nikolaos Papadopoulos, Greece

15:17 - 15:22 - **Q&A**

15:22 - 15:30 - **Does pediatric asthma primarily depend on submicrone aerosol pollutants?**

Izabele Juskiene, Lithuania

15:30 - 15:35 - **Q&A**

SYM4 Immunomodulation in respiratory allergy

16:00-17:15 CET

Moderators: Umit murat Sahiner, Turkey / Mattia Giovannini, Italy

16:00 - 16:25 - **Finding the perfect biomarker in immunotherapy for respiratory allergy**

Mohamed Shamji, United Kingdom

16:25 - 16:50 - **Adherence and routes in immunotherapy for respiratory allergy**

Adam M Chaker, Germany

16:50 - 17:15 - **Prescribing immunotherapy to pollens in children: influence of geographical and sociological diversity**

Domingo Barber, Spain

Pro&Con Session - Adrenaline auto-injectors: are they fit for purpose?

17:30-18:30 CET

Moderators: Jennifer Gerdtts, Canada / Susanne Halcken, Denmark

17:30 - 18:30 - **The arguments Pro**

Katharina Blümchen, Germany

17:30 - 18:30 - **The arguments Con**

Pablo Rodríguez del Río, Spain

SYM5 Pediatric mastocytosis: diagnosis, prognosis and management

17:30-18:45 CET

Moderators: Melody Carter, United States / Amena Warner, United Kingdom

17:30 - 17:55 - **Pediatric mastocytosis: an overview**

Sigurd Broesby-Olsen, Denmark

17:55 - 18:20 - **Differential diagnosis of elevated serum tryptase in cases other than mastocytosis**

Frank Siebenhaar, Germany

18:20 - 18:45 - **Value of c-kit mutations in the skin, peripheral blood and bone marrow in pediatric mastocytosis. What does it tell us?**

Melody Carter, United States



Saturday, 13 November 2021 - 13:00 - 14:15 CET

Group 1: Novel approaches in asthma

Moderators: *Graham Roberts, United Kingdom / Nicolette Arends, the Netherlands*

GLCCI1 gene polymorphism in children with bronchial asthma

Alena Minina, Belarus

Identification of DNA methylation markers associated with lung function in Latino youth with asthma

Esther Herrera-Luis, Spain

Biomarkers in asthma in the context of atopic dermatitis in young children

Millie Nguyen Basu, Denmark

Comparison of FENO levels with the values of spirometric parameters in children with bronchial asthma

Hanna Kasianenko, Ukraine

Multiple breath washout quality control in the multicenter setting in preschool wheeze

Catharina Nitsche, Germany

Natural history of asthma from childhood to early adulthood in hong kong children

Ting Fan Leung, Hong Kong SAR

Effects of parental smoking and tobacco smoke exposure on asthma symptoms in children

Arijana Simic, Croatia

The effect of aeroallergen sensitization on the expiratory variability index in asthmatic children

Janne Burman, Finland

Childhood asthma - the effect of asthma specialist intervention on asthma control

Yossi Rosman, Israel

Group 2: The spectrum of food allergy management and implications

Moderators: *Philippe Eigenmann, Switzerland / Audrey Dunn Galvin, Ireland*

Complacency could lead to a fatality. A cross sectional survey of food allergy practices within education establishments across west of Scotland

Rebecca Totterdell, United Kingdom

Irish schools: an uncommon location for accidental allergic reactions among children attending an allergy clinic

Miranda Crealey, Ireland

Home re-introduction of low risk food allergens

Robert Winter

Cow's milk oral immunotherapy: 5 to 10-year long-term follow-up

Isabel Elías Sáenz, Spain

A quantitative assessment of the burden of peanut allergy on children and their parents/guardians

Nick Makwana, United Kingdom

Evaluation of the clinical characteristics of patients with food protein-induced enterocolitis syndrome: A multi-center study

Azize Pinar metbulut, Turkey

Description of a french cohort of infants with cow's milk protein allergy managed in pediatricians' routine clinical practice

Christophe Dupont, France

The health economic impact of cow's milk allergy in childhood: a retrospective cohort study

Abbie Louise Cawood, United Kingdom

A qualitative analysis of the burden of peanut allergy on children and their parents/guardians

Nick Makwana, United Kingdom

Concurrent food protein induced allergic proctocolitis and igE mediated allergy: a case report

Liliana Patrícia Pereira Dias, Portugal



Saturday, 13 November 2021 - 13:00 - 14:15 CET

Group 3: Atopic and contact dermatitis

Moderators: *Suzanne Pasmans, The Netherlands / Pasquale Comberiati, Italy*

The relationship between the severity of disease and the quality of life indexes in infants with atopic dermatitis

Seda Sirin Kose, Turkey

The first clinical experiences with dupilumab for severe atopic dermatitis in children and adolescents

Mateja Starbek Zorko, Slovenia

Dupilumab - rapid and successful treatment of severe atopic dermatitis in 15 year old boy

Sónia Pereira Garcia, Portugal

Allergic contact dermatitis caused by devices for the management of type 1 diabetes in children: the alarming role of colophonium

Giovanni Battista Pajno, Italy

Allergic contact dermatitis in children and adolescents: A retrospective study

Jóni Costa Carvalho, Portugal

Genome-wide DNA methylation study of atopic dermatitis at early stages of the disease manifestation in pediatric patients

Elizaveta Bystritskaia, Russia

Ass's milk in children with atopic dermatitis: a proof of concept

Gabriele Rumi, Italy

Group 4: Immunodeficiency, COVID-19 and other infections

Moderators: *Jürgen Schwarze, United Kingdom / Wojciech Feleszko, Poland*

Assessment of the incidence and course of COVID-19 in children with asthma and allergy

Vera Kalugina, Russia

Cat allergies in children and the effects of covid-19 pandemics

Sule Buyuk Yaytokgil, Turkey

Evaluation of patient satisfaction with virtual paediatric allergy service at A DGH during the initial phase of the COVID19 pandemic in the UK: A dietetic led patient survey.

Khairy G. Gad, United Kingdom

Assessment of cmv seroprevalence in children with allergic disorder

Margarita Soloshenko, Russia

Haemophilus influenzae - a "visitor" or a "resident" for children with immunodeficiencies

Polina Shahid, Bulgaria

An antibiotic is not always the solution for a sickly child with a fever - could it be PFAFA?

Polina Shahid, Bulgaria

Team approach for more effective treatment of a child with evans-fisher syndrom

Polina Shahid, Bulgaria

Group 5: Prevention and anaphylaxis

Moderators: *Hania Szajewska, Poland / Susanne Halken, Denmark*

Timing of introduction to solid food and atopic disease in later childhood: A longitudinal cohort study
Curtis Joseph D'Hollander, Canada

Impact of probiotic microorganism lactobacillus reuteri on the prevalence of allergic diseases in slovene children
Lilijana Besednjak-Kocijancic, Slovenia

Early food allergen introduction products: who is using them, and to what extent?
Carina Venter, United States

Anaphylaxis caused by rosemary: a case report
Sara Nogueira Machado, Portugal

Barriers and challenges affecting parents use of adrenaline auto-injector in children with anaphylaxis
Ahmed Ali Elghoudi, United Arab Emirates

A case of late onset anaphylaxis to honeybee venom
Cecilia Gomes Pereira, Portugal

Food-dependent exercise-induced anaphylaxis – A case report
Josefina Vieira, Portugal

22ND EAACI - ALLERGOPHARMA RESEARCH AWARD 2022

Applications are Now Open



THE EAACI - ALLERGOPHARMA RESEARCH AWARD

EAACI and Allergopharma are pleased to announce the opening of applications for the EAACI – Allergopharma Research Award 2022.

The award should recognize scientific achievements of young scientists working in the field of allergy and encourage their engagement in further research. Therefore, the EAACI Allergopharma Research Award is open to Junior Members of EAACI, who have conducted their research in a European center.

The institution or research organization, where the awardee primarily conducts the research, will be granted with EUR 10,000. The awardee will be presented with the award during the Opening Ceremony of EAACI Congress 2022. Registration, accommodation and travel to the congress will be supported by the grant.

Any EAACI Junior Member may apply personally for the award using the online system provided.



Sponsorship and Exhibition

This section contains information that is promotional in nature, distinct from the scientific/educational elements of PAAM Digital 2021.



ALK sponsored symposium at PAAM 2021

**Raising paediatric awareness through
growing evidence for allergy immunotherapy**
- optimise the treatment of children suffering from respiratory allergy

November 13, 2021, 10-11.15 AM CET

Introduction and setting the stage for paediatric allergic disease

Dr. Priya Bansal, US

**Raising awareness of the disease burden in children and the preventive role
of allergy immunotherapy**

Prof. Graham Roberts, UK

**The growing evidence for SQ SLIT-tablet treatment in children
- symptom control and sustained long-term efficacy**

Prof. Douglas Mack, Canada

From childhood to adolescence - providing patient-tailored education

Dr. Marta Vazquez-Ortiz, UK

Panel discussion

Facilitated by Dr. Priya Bansal



EAACI Founder Sponsors



EAACI and the Local Organising Committee gratefully acknowledge the support of our 2021 Founder Sponsors.

Platinum Founder Sponsors

**Allergy
Therapeutics**

AstraZeneca



NOVARTIS

**SANOFI GENZYME
REGENERON**

STALLERGENES GREER
Life beyond allergy

Gold Founder Sponsors

allergoPharma

**hal
allergy**

Silver Founder Sponsors



ALK

LETIPharma
since 1919

**ThermoFisher
SCIENTIFIC**

Company Sponsored Symposia



Friday, 12 November 2021

COMPANY SPONSORED Session Sponsored by Nutricia

Nutricia: Latest real world data on the CMA journey; how can synbiotics reduce the health burden for infants and their families?

11:30 - 12:45 CET

Moderator: *Rosan Meyer, UK*

- **Infants/young children living with CMA have an increased health burden**
Speaker: *Kate Grimshaw, UK*
- **Modulating the gut microbiota and improving immune outcomes**
Speaker: *Rebecca Stratton, UK*
- **Case Studies**
Speakers: *Maria Eugenia Gervasoni, Argentina; Gemma Castillejo, Spain*
- **Closing & Key messages**
Moderator: *Rosan Meyer, UK*

COMPANY SPONSORED Session Sponsored by DBV Technologies



DBV Technologies: Patients with peanut allergy: emerging solutions for a comprehensive management

13:00 - 14:15 CET

Moderators: *Montserrat Alvaro Lozano, Spain; Christian Vogelberg, Germany*

- **Introduction: Current status of peanut allergy management in Europe**
Speaker: *Montserrat Alvaro Lozano, Spain*
- **Peanut immunotherapy: to a standardized approach**
Speaker: *Andre Knulst, The Netherlands*
- **Peanut allergy management in a digital world**
Speaker: *Stephanie Dramburg, Germany*
- **Conclusion**
Speaker: *Christian Vogelberg, Germany*

Company Sponsored Symposia



Friday, 12 November 2021

COMPANY SPONSORED Session
Sponsored by Nestlé Nutrition Institute



Nestlé Nutrition Institute: The link between early diet and food allergy
14:30 - 15:45 CET

- **Introduction**
Speaker: *Liam O'Mahony, Ireland*
- **Early interventions and long lasting effect on childhood allergies: The GINI study 20y results**
Speaker: *Monika Gappa, Germany*
- **How do maternal diet and infant complementary feeding influence food allergy**
Speaker: *Carina Venter, USA*
- **What do existing food allergy prevention studies tell us? What does the future hold?**
Speaker: *Kari Nadeau, USA*
- **Live Q&A**
Speakers: *Liam O'Mahony, Ireland; Monika Gappa, Germany; Carina Venter, USA; Kari Nadeau, USA*

COMPANY SPONSORED Session
Sponsored by Sanofi Genzyme & Regeneron



Sanofi Genzyme / Regeneron: Childhood asthma and the impact of type 2 inflammation
16:00 - 17:15 CET

- **Opening remarks**
Speakers: *Leonard Bacharier, USA; Nikolaos Papadopoulos, Greece*
- **The burden of childhood asthma**
Speaker: *Nikolaos Papadopoulos, Greece*
- **Allergic asthma and type 2 inflammation in childhood**
Speaker: *Leonard Bacharier, USA*
- **Panel Discussion: Type 2 inflammation in childhood asthma**
Speakers: *Leonard Bacharier, USA; Nikolaos Papadopoulos, Greece*
- **Audience Q&A**
Speakers: *Leonard Bacharier, USA; Nikolaos Papadopoulos, Greece*
- **Closing remarks**
Speakers: *Leonard Bacharier, USA; Nikolaos Papadopoulos, Greece*

Company Sponsored Symposia



Saturday, 13 November 2021

COMPANY SPONSORED Session
Sponsored by ALK



ALK: Raising paediatric awareness through growing evidence for allergy immunotherapy - optimise the treatment of children suffering from respiratory allergy
10:00 - 11:15 CET

- **Introduction and setting the stage for paediatric allergic disease**
Speaker: *Priya Bansal, USA*
- **Raising awareness of the disease burden in children and the preventive role of allergy immunotherapy**
Speaker: *Graham Roberts, UK*
- **The growing evidence for SQ SLIT-tablet treatment in children - symptom control and sustained long-term efficacy**
Speaker: *Douglas Mack, Canada*
- **From childhood to adolescence - providing patient-tailored education**
Speaker: *Marta Vazquez-Ortiz, UK*
- **Panel Discussion**
Speaker: *Priya Bansal, USA; Graham Roberts, UK; Douglas Mack, Canada; Marta Vazquez-Ortiz, UK*

COMPANY SPONSORED Session
Sponsored by Aimmune Therapeutics



Aimmune: Treating peanut allergy with oral immunotherapy: new data and practical experience
11:30 - 12:45 CET

Moderator: *Jonathan Hourihane, Ireland*

- **Introduction**
Speaker: *Jonathan Hourihane, Ireland*
- **Key phase 3 clinical data**
Speaker: *Kirsten Beyer, Germany*
- **Data update**
Speaker: *Jonathan Hourihane, Ireland*
- **Panel discussion: key learnings from practical experience**
Speakers: *Jonathan Hourihane, Ireland; Kirsten Beyer, Germany; Janet Beausoleil, USA*
- **Live Q&A session**
Speakers: *Jonathan Hourihane, Ireland; Kirsten Beyer, Germany; Janet Beausoleil, USA*

Company Sponsored Symposia



COMPANY SPONSORED Session
Sponsored by Uriach

Uriach: How can we improve the approach to treating chronic urticaria in children?

16:00 - 17:15 CET

Moderator: Montserrat Álvaro, Spain

- **Management of pediatric chronic urticaria patients: the gap between guidelines and practice**
Speaker: Montserrat Álvaro, Spain
- **The prevalence and pathogenesis of chronic urticaria in children**
Speaker: Stefania Arasi, Italy
- **The added value of rupatadine in pediatric chronic urticaria**
Speaker: Vicky Xepapadaki, Greece
- **Discussion and Q&A**
Speaker: Montserrat Álvaro, Spain

Exhibitor & Sponsor List

Click on the icons
to access content



Exhibitors and Sponsors	Virtual Exhibition	Digital Session
Aimmune Therapeutics		
ALK		
DBV Technologies		
Nestlé Nutrition Institute		
Novartis		
Nutricia		
Sanofi Genzyme & Regeneron		
ThermoFisher Scientific		
Uriach		

Exhibitor & Sponsor Editorials



Aimmune Therapeutics

10 Eastbourne Terrace
W2 6LG, London
United Kingdom
+44 20 86290240
www.aimmune.co.uk

Aimmune Therapeutics, a Nestlé Health Science Company, is a biopharmaceutical company developing and commercialising treatments for potentially life-threatening food allergies and other food-mediated conditions. Aimmune was founded to address the need for approved treatments for food allergies, starting with peanut allergy. In 2020, Aimmune became the first company to have a treatment for peanut allergy that is both FDA and UK and EU-approved. Aimmune's development pipeline also includes investigational candidates for other prevalent food allergies, including multi-tree nut. For more information, visit www.aimmune.co.uk.

ALK – Abello

Boege Alle 1
2970, Hoersholm
Denmark
+45 45 747576
www.alk.net

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing. ALK has worked with the allergy community and conducted large clinical trial programmes enrolling more than 23,000 patients to support evidence-based AIT with SLIT-tablets across the most common respiratory allergies demonstrating consistent efficacy and safety (incl. SLIT-tablets for allergy caused by house dust mite and pollen from grass, tree, ragweed and Japanese cedar). More than half of ALK's SLIT-tablets are already available to children and adolescents, but we continue to conduct further clinical trials in paediatric populations to make SLIT-tablets available to all age groups within the most common respiratory allergies.

DBV Technologies

177-181, avenue Pierre Brossolette
92120, Montrouge
France
+33 (0)1 55 42 78 78
www.dbv-technologies.com

DBV Technologies is a global biopharmaceutical company that is developing an investigational epicutaneous immunotherapy treatment option for the millions of people suffering from food allergies and other immunological disorders. Starting with peanut, we are investigating food allergy treatments that aim to safely reduce the risk of unpredictable, life-threatening reactions due to accidental exposure.

Nestlé Health Institute

Route du Jorat 57
1000, Lausanne
Switzerland
+41 021 924 4100
www.nestlehealthscience.com

Nestlé Health Science is a globally recognized leader in the science of nutrition. It is committed to empowering healthier lives and has an industry-leading portfolio of medical nutrition, consumer care and pharmaceutical solutions, with food allergies as a key pillar. Visit www.nestlehealthscience.com. The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals in all parts of the world. NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at <http://www.nestlenutrition-institute.org>.



Novartis

CH-4056, Basel
Switzerland
+41 61 697 1111
www.novartis.com

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at <https://www.novartis.com>.

Sanofi Genzyme and Regeneron

50 Binney Street
02142, Cambridge, MA
United States of America
+1 800 981 2491
www.sanofigenzyme.com
www.regeneron.com

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

Nutricia

Taurusavenue 167
2132 LS, Hoofddorp
The Netherlands
+31 (0) 20 456 9000
www.danone.com

Building on 125 years of research, innovation and care, Nutricia pioneers medical nutrition that helps enable life-changing and life-saving health outcomes, so that people can live their life to its fullest. Nutricia supports healthy growth and development in early life and plays its part addressing some of the world's biggest health challenges from birth through to old age. The Nutricia portfolio includes a wide range of nutritional solutions for pre-term birth, faltering growth, food allergy, and rare metabolic diseases.

Uriach

Avinguda Camí Reial, 51
08184, Barcelona
Spain
+34 938 64 96 92
www.uriach.com

Uriach is a private Spanish pharmaceutical company based in Barcelona. In the pharmaceutical business since 1838, it is one of the leading domestic companies. Over 60 years of continuous devotion to R&D and a team of highly qualified professionals have allowed Uriach to commercialize our products in more than 70 countries. Rupaadine, a modern second-generation and potent antihistamine with PAF-antagonist activity is Uriach's contribution to the treatment of allergic conditions in children and adults.



Thermo Fisher Scientific


Rapsgatan 7P
SE-751 37, Uppsala
Sweden
+46 1 8165000
www.thermoscientific.com/phadia

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Our complete blood test systems support the clinical diagnosis of allergy, asthma and autoimmune diseases. With 1,800 employees worldwide in ImmunoDiagnostics, we are a global leader in in-vitro allergy diagnostics and a European leader in autoimmunity diagnostics. The allergy and autoimmunity product lines operate on a common automated instrument platform, which supports both productivity and cost efficiencies in clinical laboratories around the world.



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

Save the
date!



EAACI Hybrid Congress 2022

Prague, Czech Republic 1-3 July

*Common origins of allergy and chronic inflammatory
diseases - One Health approach*

EAACI.ORG

E

E

E

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EA

RG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG

EAACI.ORG